These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 22121999)

  • 41. The use of antipsychotics in obsessive compulsive disorder.
    Conti D; Girone N; Boscacci M; Casati L; Cassina N; Cerolini L; Giacovelli L; Viganò C; Conde MM; Cremaschi L; Dell'Osso BM
    Hum Psychopharmacol; 2024 May; 39(3):e2893. PubMed ID: 38340275
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An open trial of aripiprazole augmentation for SSRI non-remitters with late-life depression.
    Rutherford B; Sneed J; Miyazaki M; Eisenstadt R; Devanand D; Sackeim H; Roose S
    Int J Geriatr Psychiatry; 2007 Oct; 22(10):986-91. PubMed ID: 17340654
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Possible neuroleptic malignant syndrome with aripiprazole and fluoxetine.
    Duggal HS; Kithas J
    Am J Psychiatry; 2005 Feb; 162(2):397-8. PubMed ID: 15677611
    [No Abstract]   [Full Text] [Related]  

  • 44. Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder.
    Lorenz RA; Jackson CW; Saitz M
    Pharmacotherapy; 2010 Sep; 30(9):942-51. PubMed ID: 20795849
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chronic catatonia with obsessive compulsive disorder symptoms treated with lorazepam, memantine, aripiprazole, fluvoxamine and neurosurgery.
    Mukai Y; Two A; Jean-Baptiste M
    BMJ Case Rep; 2011 Aug; 2011():. PubMed ID: 22687661
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Successful treatment of comorbid obsessive-compulsive disorder with aripiprazole in three patients with bipolar disorder.
    Uguz F
    Gen Hosp Psychiatry; 2010; 32(5):556-8. PubMed ID: 20851277
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.
    Dold M; Aigner M; Lanzenberger R; Kasper S
    Int J Neuropsychopharmacol; 2015 May; 18(9):. PubMed ID: 25939614
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms: an open-label study of 15 patients.
    Glick ID; Poyurovsky M; Ivanova O; Koran LM
    J Clin Psychiatry; 2008 Dec; 69(12):1856-9. PubMed ID: 19026264
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study.
    Pfanner C; Marazziti D; Dell'Osso L; Presta S; Gemignani A; Milanfranchi A; Cassano GB
    Int Clin Psychopharmacol; 2000 Sep; 15(5):297-301. PubMed ID: 10993132
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Muscatello MR; Bruno A; Pandolfo G; Micò U; Scimeca G; Romeo VM; Santoro V; Settineri S; Spina E; Zoccali RA
    J Clin Psychopharmacol; 2011 Apr; 31(2):174-9. PubMed ID: 21346614
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical Recommendations for Augmentation Agents in Obsessive-Compulsive Disorder Partially Responsive to Serotonin Reuptake Inhibitors.
    Gautam M
    J Clin Psychopharmacol; 2023 Jul-Aug 01; 43(4):369-377. PubMed ID: 37335203
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of Ziprasidone Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: A 12-Week, Open-Label Uncontrolled Preliminary Study.
    Bruno A; Pandolfo G; Cedro C; Gallo G; De Felice M; Zoccali RA; Muscatello MR
    Clin Neuropharmacol; 2016; 39(1):6-9. PubMed ID: 26757309
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.
    Bogetto F; Bellino S; Vaschetto P; Ziero S
    Psychiatry Res; 2000 Oct; 96(2):91-8. PubMed ID: 11063782
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
    McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH
    Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Serotonin reuptake inhibitor-cognitive behavioural therapy-second generation antipsychotic combination for severe treatment-resistant obsessive-compulsive disorder. A prospective observational study.
    Tundo A; Salvati L; Cieri L; Balestrini V; Di Spigno D; Orazi F; Iommi M; Necci R
    Int J Psychiatry Clin Pract; 2022 Nov; 26(4):395-400. PubMed ID: 35323098
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study).
    Fava M; Mischoulon D; Iosifescu D; Witte J; Pencina M; Flynn M; Harper L; Levy M; Rickels K; Pollack M
    Psychother Psychosom; 2012; 81(2):87-97. PubMed ID: 22286203
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Do antipsychotics ameliorate or exacerbate Obsessive Compulsive Disorder symptoms? A systematic review.
    Sareen J; Kirshner A; Lander M; Kjernisted KD; Eleff MK; Reiss JP
    J Affect Disord; 2004 Oct; 82(2):167-74. PubMed ID: 15488245
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A benzisothiazole derivative and antipsychotic agent, perospirone, for augmentation of selective serotonin reuptake inhibitors (SSRIs) in refractory obsessive-compulsive disorder (OCD): two patient case series.
    Matsunaga H; Matsui T; Ohya K; Okino K; Hayashida K; Maebayashi K; Kiriike N; Stein DJ
    Int J Psychiatry Clin Pract; 2006; 10(2):142-5. PubMed ID: 24940965
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder.
    Menza MA; Dobkin RD; Marin H
    J Clin Psychopharmacol; 2007 Apr; 27(2):207-10. PubMed ID: 17414231
    [No Abstract]   [Full Text] [Related]  

  • 60. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Mohr N; Vythilingum B; Emsley RA; Stein DJ
    Int Clin Psychopharmacol; 2002 Jan; 17(1):37-40. PubMed ID: 11800505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.